Four new projects funded through Genome Canada’s Genomics Applications Partnership Program (GAPP) will harness the power of genomics to transform Canadian healthcare by enabling quicker diagnosis and improved treatment plans.
Announced in December 2023, a new investment of $41 million will support the latest round of GAPP projects, fueling late-stage research and development (R&D) projects addressing real world opportunities and challenges, including a $28.7 million investment in precision health treatment and diagnosis.
FOUR NEW PROJECTS ADVANCING HEALTHCARE FOR CANADIANS
Development of a novel cyclin K degrader of high-risk AML patients and associated genomic features
- Guy Sauvageau (Université de Montréal) and Anne Mariner (RejuvenRx Inc.) will validate and commercialize a new cancer drug to treat high-risk acute myeloid leukemia patients.
EpiSign international: Health system impact assessment and expanding clinical utilization of epi/genomic testing in rare diseases and beyond
- Bekim Sadikovik (Lawson Health Research Institute; London Health Sciences Centre) and Dr. Rishi Porecha (Illumina Inc.) will improve and speed up diagnosis of rare genetic diseases.
Improving patient matching to therapy (PMATCH): Streamlining clinical trial criteria to guide precision oncology
- Benjamin Haibe-Kains and Dr. Trevor Pugh (University of Toronto) and Janet Dancey (Canadian Cancer Clinical Trials Network, 3CTN) will optimize the matching of patients to precision medicine clinical trials.
Predict to prevent: A novel genomic-derived score to improve the prognosis of Type 2 (T2) diabetes patients at high risk of complications
- Pavel Hamet (Université de Montréal), Johanne Tremblay (OPITHERA) and Laurent Amram (ELNA Medical Group) will bring early and personalized disease management for Type 2 diabetes patients at high risk of complications and reduce overtreatment of low-risk individuals.
To learn more about this investment in genomic research and development, click here.
ABOUT GAPP
The Genomic Applications Partnership Program (GAPP) supports industry-facing partnered research projects that address real-world challenges. Designed to accelerate the social and economic impact of genomics, GAPP provides the space for research, innovation and application to thrive collaboratively. GAPP projects address real-world challenges and opportunities through greater collaboration between genomics scientists and the users of genomics research. They aim to stimulate public- and private-sector investment in Canadian genomics technologies, advancing technology uptake in receptors and moving technologies across readiness levels.